Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Litton

Showing results (131-140 of 157) with videos related to

Pageof 16
Sort By:
Cell Reports. Medicine|June 5, 2024
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness"Bora Lim, Sahil Seth, Clinton Yam, et al.
Frontiers in Oncology|November 9, 2023
Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancerBikash Panthi, Rania M Mohamed, Beatriz E Adrada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2022
Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast CancerClinton Yam, Nour Abuhadra, Ryan Sun, et al.
Scientific Reports|January 20, 2023
Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRIZijian Zhou, Beatriz E Adrada, Rosalind P Candelaria, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|December 12, 2023
Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIsZijian Zhou, Beatriz E Adrada, Rosalind P Candelaria, et al.
Cancers|July 14, 2023
Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective TrialNour Abuhadra, Ryan Sun, Clinton Yam, et al.
NPJ Breast Cancer|November 20, 2025
Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancerMary S Guirguis, Beatriz E Adrada, Clinton Yam, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†A M Gonzalez-Angulo, A Akcakanat, S Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2021
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian CancerShannon N Westin, Marilyne Labrie, Jennifer K Litton, et al.
Cancers|March 28, 2025
Deep Learning Models Based on Pretreatment MRI and Clinicopathological Data to Predict Responses to Neoadjuvant Systemic Therapy in Triple-Negative Breast CancerZhan Xu, Zijian Zhou, Jong Bum Son, et al.
Pageof 16

Showing results (131-140 of 157) with videos related to

Sort By:
Pageof 16
Cell Reports. Medicine|June 5, 2024
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness"Bora Lim, Sahil Seth, Clinton Yam, et al.
Frontiers in Oncology|November 9, 2023
Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancerBikash Panthi, Rania M Mohamed, Beatriz E Adrada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2022
Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast CancerClinton Yam, Nour Abuhadra, Ryan Sun, et al.
Scientific Reports|January 20, 2023
Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRIZijian Zhou, Beatriz E Adrada, Rosalind P Candelaria, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|December 12, 2023
Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIsZijian Zhou, Beatriz E Adrada, Rosalind P Candelaria, et al.
Cancers|July 14, 2023
Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective TrialNour Abuhadra, Ryan Sun, Clinton Yam, et al.
NPJ Breast Cancer|November 20, 2025
Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancerMary S Guirguis, Beatriz E Adrada, Clinton Yam, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†A M Gonzalez-Angulo, A Akcakanat, S Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2021
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian CancerShannon N Westin, Marilyne Labrie, Jennifer K Litton, et al.
Cancers|March 28, 2025
Deep Learning Models Based on Pretreatment MRI and Clinicopathological Data to Predict Responses to Neoadjuvant Systemic Therapy in Triple-Negative Breast CancerZhan Xu, Zijian Zhou, Jong Bum Son, et al.
Pageof 16